Overview

Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to develop biomarkers for central nervous system BH4 concentration in children with autism so they can be easily screened to determine if they may benefit from BH4 supplementation. Kuvan is a synthetic form of BH4. BH4 is an enzyme cofactor that is essential for several critical metabolic functions.
Phase:
N/A
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborator:
BioMarin Pharmaceutical
Treatments:
Verapamil